Lilly Asia Ventures - Backing the Innovation of China's Biomedical Industry

SHANGHAI, Dec.17, 2015 /PRNewswire/ – Recently, Biodiscover, an independent biomedical media company, ranked the top ten innovative biopharmaceutical companies in China. 4 out of 10 top companies are captured in Lilly Asia Ventures (LAV)'s portfolio, including Chipscreen, Innovent, Betta Pharma and 3S Bio (The other six companies are Hengrui, Luye, Kanghong, Ascletis, Simcere, and Hutchinson. Source:
"We are proud of this result and honored to have supported four of the ten frontrunners in China healthcare innovation," commented Dr. Yi Shi, LAV's Managing Partner. "This list reflects our expertise in biomedical industry and validates our investment strategy - we bet on solid science and exceptional management team and leverages our domain expertise and resources to create value for portfolio companies post investment."
Founded in 2008 and headquartered in Shanghai, LAV has invested in over 30 companies globally, with strong focus on China. LAV's portfolio covers all major sectors of the biomedical and healthcare industry including biopharmaceuticals, medical devices, diagnostics and healthcare services.
"Looking ahead, we are blessed with a quickly expanding talent pool, favorable innovation and funding environment, and strong government support. The best is yet to come." Dr. Shi remains optimistic of China biomedical market: "LAV will continue partnering with ambitious entrepreneurs with high integrity, helping them develop and commercialize high quality medical products that contribute to global health."

Nicole Liu
[email protected]


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.